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128 Poster Session-IIStandard primary therapy for acute graft-vs.-host disease
(GVHD) is systemic corticosteroids, but failure of systemic steroids
to control acute GVHD is common and can result in very high non-
relapse mortality. Overall, fewer than 30% of patients with systemic
steroid resistant GVHD have complete or partial responses to avail-
able therapy, and 1 year survival remains 15% or less. There has been
no generally accepted therapy for systemic steroid-refractory acute
GVHD. Although little data on localized therapy for GVHD is pub-
lished, intra-arterial injection of high-dose corticosteroids appears to
be a viable option and sporadic publications have demonstrated sev-
eral positive outcomes in patients receiving intra-arterial steroids.
We report on 17 patients with systemic steroid resistant GVHD
who have been treated with intra-arterial injections of high-dose cor-
ticosteroids at our institution in the past 2 years. A total of 23 treat-
ments were performed with only three patients receiving more than
one treatment. Sixteen of the patients received treatment for GI
GVHD, of which three had concomitant hepatic involvement.
One received treatment for hepatic GVHD only. The patient with
isolated hepatic GVHD received treatments into the hepatic arteries
and all patients with GI GVHD received treatments into the supe-
rior and inferior mesenteric arteries. Six of the patients (35%) dem-
onstrated no response, and of those 3 died of GVHD and 3 died of
other complications. Five patients (29%) showed partial response.
Of these, 4 were discharged on TPN and oral meds 14 to 43 days af-
ter the intra-arterial treatment, the fifth patient became septic prior
to discharge and expired. The remaining six patients (35%) showed
complete response and were discharged on PO diet and oral meds 1
to 22 days after the intra-arterial treatment. No immediate treatment
or procedure related complications were noted. These preliminary
results reinforce that direct intra-arterial injection of methylprednis-
olone appears to be effective and safe in patients that have proven to
be resistant to systemic steroids. In two patients, one with a complete
and the other with a partial response, there was recurrence of
GVHD. These patients raise the question of whether more than
one initial treatment may be helpful in preventing recurrence.
Larger, prospective studies need to be conducted to further evaluate
this promising approach to systemic steroid refractory GVHD.
Patient Characteristics, Response, and Current Status
Location Duration Number CurrentAge/
Sex Diagnosisof
DiseasePrior
Treatmentto
Responseof
Treatments ResponseStatus (days
post IAS)63/F NHL GI IVS, INF 14 days 1 PR no GVHD (713)48/M NHL GI IVS, ATG,
INF x2, MSC21 days 1 PR cGVHD (564)58/M NHL GI IVS 12 days 1 PR D, ARDS, no
GVHD (42)41/F MM GI IVS, ATG 43 days 1 PR D, ARDS, no
GVHD (53)50/F AA GI IVS, ATG 12 days 1 CR cGVHD of
Lungs, no GI
GVHD (562)70/M NHL Hepatic IVS, ATG 22 days 1 CR no GVHD (735)60/M NHL GI IVS, INF 1 day 1 CR no GVHD (568)50/F NHL GI IVS 19 days p 1st,
7 days p 2nd2 CR no GVHD (700)71/M NHL GI IVS, INF x4,
ATG5 NR D, GVHD (15)55/M NHL GI IVS 7 days 1 CR D - perforation
secondary to
CMV colitis
(404)39/F NHL GI IVS 1 NR D, GVHD, CMV
colitis (56)70/F NHL GI IVS 1 NR D, GVHD,
sepsis (50)38/M NHL GI IVS 1 NR D, GVHD (15)60/F NHL GI IVS, INF 24 days 1 CR D, recurrent
GVHD (498)59/M NHL GI IVS, INF 2 NR D, GVHD (11)61/F MDS/
NHLGI IVS 14 days 1 PR D, sepsis, no
GVHD (34)(Continued ). (Continued )Age/
Sex DiagnosisLocation
of
DiseasePrior
TreatmentDuration
to
ResponseNumber
of
Treatments ResponseCurrent
Status (days
post IAS)50/M MDS/
NHLGI IVS, ATG 1 NR D, GVHD,
sepsis (32)IAS indicates intra-arterial steroids; NHL, non hodgkin’s lymphoma; MM,
multiple myeloma; AA, aplastic anemia; MDS, myelodysplastic syn-
drome; GI, gastrointestinal; IVS, intra-venous steroids; ATG, anti-thymo-
cyte globulin; INF, infliximab; MSC, mesenchymal stem cells; PR, partial
response; CR, complete response; NR, no response; D, dead; GVHD,
graft-vs-host disease; cGVHD, chronic GVHD; ARDS, acute respiratory
distress syndrome; CMV, cytomegalovirus.357
THERAPY OF STEROID-REFRACTORY ACUTE GvHD WITH CD52 ANTI-
BODY ALEMTUZUMAB IS EFFECTIVE AND SAFE
Gramatzki, M.1, Schrauder, A.2, Schub, N.1, Guenther, A.1, Ehlert, C.1,
Repp, R.1 1University of Kiel, Kiel, Germany; 2University of Kiel, Kiel,
Germany
Although in recent years techniques of allogeneic hematopoietic
stem cell transplantation have improved considerably to allow the
use of this procedure even for elderly and less fit patients, severe
graft-versus-host disease (GvHD) remains themain obstacle to apply
this therapeutic modality. Still, no standard therapy has been identi-
fied once a patient has developed severe acute GvHD and is refrac-
tory to high-dose steroids. The pre-emptive use of CD52 antibody
alemtuzumab as part of the conditioning regimen may lead unneces-
sarily to relapse and increased infection rates. Commercially avail-
able alemtuzumab was used in 16 patients now evaluable, age
range 13 to 68 years, with GvHD grade III and IV refractory to at
least 7 days of high-dose steroids. Patients had undergone stem
cell transplantation from family donors (n5 7) or matched unrelated
donors (n 5 9). Four had 1 or 2 antigen mismatch. All patients had
severe gut and/or liver involvement. Initially, in three patients in
rather critical situations start doses of alemtuzumab in the range of
70mg to 80mg (total) were applied in fractions over several days
and repeated after 3 to 4 weeks. Impressive responses, such as biliru-
bin levels of 48mg/dl returning to normal within several weeks, were
encouraging, but virus reactivation and bacterial infections were
seen. This finding and considering the limited quantities of lym-
phoid tissue present early after transplantation requiring less anti-
body, the starting dose was reduced to 20 to 33 mg in the second,
and 5–10mg in the third cohort, repeated every 2 to 3 weeks. CR,
or near CR, were obtained in 11 of 13 patients of these two dosage
groups. The longest follow-up is 138 months. Chronic GvHD
was frequently observed. Pronounced lymphocyte depletion seems
inevitable for efficacy, but infectious complications were limited.
Thus, despite the need for close observation for infectious complica-
tions, alemtuzumab given sequentially in moderate doses has a sub-
stantial activity in severe steroid-refractory acute GvHD.358
EXTRACORPOREAL PHOTOPHERESIS THERAPY FOR CHRONIC GRAFT-
VERSUS-HOST DISEASE: RESPONSE IS ASSOCIATED WITH CONTENT OF
DENDRITIC CELLS AND T-CELLS IN PERIPHERAL BLOOD AT INITIATION
OF TREATMENT
Akhtari, M.1, Giver, C.R.1, Renfroe, H.M.1, Langston, A.A.1,
Khoury, H.J.1, Flowers, C.R.1, Kaufman, J.L.1, Lonial, S.1,
Lechowicz, M.J.1, Gleason, C.L.1, Vaughn, L.2, Waller, E.K.1 1Emory
University School of Medicine, Atlanta, GA; 2Emory University Hospital,
Atlanta, GA
Background:Extracorporeal photopheresis (ECP) is used to treat
cGVHD, but its mechanism has not been fully defined. One model
for the mechanism of ECP in cGVHD is dendritic cell (DC) deple-
tion andT-cell modification.We tested this hypothesis by determin-
ing the numbers of circulating DCs and T-cells prior to ECP and
Poster Session-II 129during therapy in patients with cGVHD, and correlating cell num-
bers with response.
Methods:We studied 25 adult pts with histories of hematological
malignancies who developed cGVHD after allogeneic, HLA-
matched HPCT. At the time of ECP initiation, pts were either de-
pendent upon corticosteroids for control of cGvHD (21 pts), or ste-
roid-intolerant (4 pts). A good response was defined as having. 50%
reduction in the corticosteroid dose within 4 months of starting
ECP, with improved or stable lesions on skin and other sites. For ste-
roid-intolerant pts, improvement in skin condition was used to iden-
tify responders. PBMCs were analyzed before ECP began and every
2 months during ECP therapy. The numbers of plasmacytoid DCs
(pDC, Lin-CD1231CD11c-HLA-DR1), myeloid DCs (mDC,
Lin-CD123-CD11c1HLA-DR1), and CD41 and CD81 T-cells
in blood were determined by flow cytometry.
Results:Themedian number of ECP treatments was 26 (range 2–
68). Fourteen pts (56%) had good response, and 11 were non-re-
sponders. Responders had an estimated 2-yr survival of 88% after
starting ECP, vs 18% for non-responders (p 5 0.004). Responders
had higher baseline numbers of pDCs (average 5.8 vs. 0.6 cells/
mcL, p 5 0.025) and mDCs (average 15 vs. 3.8 cells/mcL, p 5
0.01) compared with non-responders. Baseline CD41 T-cell num-
bers were higher in responders compared with non-responders (av-
erage 623 vs. 178 cells/mcL, p 5 0.005), as were CD81 T-cell
numbers (712 vs. 251 cells/mcL, p 5 0.047). There was no correla-
tion between incidence of infection and numbers of T-cells or DCs,
or response to ECP. Contrary to the original hypothesis, there were
no consistent changes in the numbers of circulating DCs and T-cells
among responders over a 12-month period.
Conclusion:Our results demonstrate that higher numbers of cir-
culating DCs and T-cells predict response to ECP in pts with
cGVHD. Response to ECP was significantly associated with im-
proved survival in univariate and multivariate analyses (p\0.03).
Our findings support a newer model for the mechanism of response
to ECP therapy, involving interactions between donor-derived DCs
and donor T-cells.359
POST-TRANSPLANT IMMUNOTHERAPY FOR PEDIATRIC ALL
Qin, H., Capitini, C.M., Wayne, A.S., Fry, T.J. National Institutes of
Health, Bethesda, MD
Background: Pediatric Acute Lymphoblastic Leukemia (ALL) is
the most common childhood malignancy. Despite substantial ad-
vancements in upfront therapy, management of patients with relapse
remains one of the difficult challenges in pediatric oncology. Alloge-
neic transplantation can be curative for relapsing ALL, in part due to
a graft versus leukemia effect. The ability to develop these ap-
proaches has been limited by lack of suitable pre-clinical models of
pediatric ALL. Thus, we sought to develop a murine model of pedi-
atric ALL to explore post-transplant immunotherapeutic strategies.
Methods: E2A-PBX1 is a translocation that occurs in approxi-
mately 5% of pediatric ALL. We utilized leukemia cells from
E2A-PBX1 transgenic/CD3epsilon -/- mice that spontaneously de-
velop precursor B cell ALL (Bijl J. et al. Gene & Development
19:224–233, 2005) to establish a transplantable ALL model.
Results: After conditioning in stem cell media, E2a-PBX1 cells
could be cultured in vitro and generated leukemia consistently.
The phenotype and pattern of dissemination is analogous to pediat-
ric pre-B ALL. Immunization with dendritic cells (DC) pulsed with
irradiated E2A-PBX1 cells protected against the development of leu-
kemia.We next sought to establish a bonemarrow transplant (BMT)
model of minimal residual disease (MRD). Injection of E2A-PBX1
cells prior to lethal irradiation and injection of minor MHC antigen
mismatched BMT resulted in the development of leukemia in two to
four weeks post BMT thus mimicking a model of minimal residual
disease. Ongoing experiments are exploring the ability to treat
MRD with DC vaccination, adoptive T cell transfer, drugs or com-
bination therapy.
Conclusions:We have established a transplantable model of pre-
B cell ALL that mimics pediatric ALL, can be prevented by vaccines,
and develop following anMRD state in allogeneic BMT.This model
provides an excellent system to test strategies to diminish relapse fol-
lowing allogeneic transplantation for pediatric ALL.360
DAY7 TNFR1 LEVELS FOLLOWING REDUCED INTENSITY ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT (HCT) PREDICT FOR ACUTE
GVHD
Kitko, C.L., Mineishi, S., Braun, T., Choi, S.W., Jones, D., Harris, A.,
Khaled, Y., Krijanovski, O., Paczesny, S., Peres, E., Yanik, G.,
Whitfield, J., Ferrara, J.L., Levine, J.E. University of Michigan, Ann
Arbor, MI
Tumor necrosis factor-a (TNF) is significant in the pathogenesis
of GVHD. We have previously shown that early rises in soluble
TNF receptor 1 (TNFR1) levels measured on day 7 following mye-
loablative (MA) allogeneic HCT predict the development of GVHD
and TRM. In the setting of reduced intensity conditioning (RIC)
GVHD rates are similar to MA even though GVHD onset is often
delayed. We therefore hypothesized that TNFR1 levels on day 7
would correlate with GVHD after RIC. TNFR1 levels were mea-
sured on day 7 post-HCT in 156 pts (median age 56.6y, range 7–
71y) who underwent RIC HCT between 2000 to 2008. Pre-HCT
conditioning was Fludarabine (125–180 mg/m2) and Busulfan (6.4–
8.0 mg/kg) 6 total lymphoid irradiation (2–4 Gy) in 142 pts, with
minor variations in 14 pts, including 6 that received ATG. GVHD
prophylaxis was tacrolimus (day -3 to 180) and short-course metho-
trexate (5 mg/m2 on day 1,3,6,11 in 99 pts) or mycophenolate (day 0–
28 in 57 pts). There were 47 related donor (RD) pts (30%), 109 un-
related donor (URD) pts (70%) and 34 pts received single antigen
mismatched HCT (6 RD, 28 URD). The incidence of GVHD 2–4
was 49% in URD and 39% in RD. The median day of GVHD onset
was 32d (range 6–162d); 56d in the RD and 30d in the URD (p 5
0.02). The logarithm of TNFR1 levels was used for the analysis in
order to normalize right-skewed values. Regression analysis revealed
that a doubling in day 7 TNFR1 levels increased the risk of GVHD
2–4 by 1.36 times (p5 0.007), however, the risk appeared to be pri-
marily in the URD pts [Table 1]. Consistent with this observation,
the median day 7 TNFR1 level was significantly higher in pts devel-
oping GVHD 2–4 after URD (11.4 vs 11.0, p 5 0.01), but not after
RD RIC HCT (11.3 vs 11.1, p 5 0.38). Using the median TNFR1
level in URD HCT as a threshold, we found that pts with day 7
TNFR1 levels above the median were more likely to develop
GVHD 2–4 (p 5 0.008). This correlation remained significant
(p 5 0.01) after adjustment for pt age, gender and HLA match.
We conclude that for pts undergoing RIC HCT, a higher day 7
TNFR1 level correlates with incidence of GVHD 2–4. This effect
of TNFR1 on GVHD was strongest in the URD setting where do-
nor response to host alloantigens is more robust and GVHD de-
velops more quickly. The informative value of a day 7 TNFR1
level decreases in RD pts who develop GVHD a median of 7 weeks
later, suggesting that GVHD in the RD RIC setting is not strongly
dependent on conditioning induced TNF release.
Association of TNFR1 with Risk of GVHD 2-4
Donor Risk Ratio* p-valueOverall (n5156) 1.36 0.007
RD (n547) 1.22 0.44
URD (n5109) 1.42 0.006*Risk Ratio is for a doubling of TNFR1 levels361
DENILEUKIN DIFITOX (ONTAK) FOR THE TREATMENT OF ADVANCED
STEROID-REFRACTORY GVHD: SINGLE INSTITUTION EXPERIENCE
Abar, F.1, Leis, J.F.2, Jacoby, C.E.1, Mishra, M.1, Bubalo, J.S.1,
Curtin, P.T.3, Hayes-Lattin, B.L.1, Meyers, G.1, Slater, S.E.1,
Subbiah, N.1, Maziarz, R.T.1 1OHSU; 2Mayo; 3UCSD
Steroid Resistant (SR)-GVHD is associated with high mortality
when in encountered in allogeneic stem cell transplantation . Deni-
leukin Diftitox (DD), a recombinant fusion protein composed of the
cytocidal A chain of Diphtheria toxin and binding portion of IL-2,
has potent activity against activated CD251 T cells important in
the etiology of GVHD. It has been reported that DDmay have ther-
apeutic activity for the treatment of SR-GHVD (Ho et al, BLOOD
2004). This approach was adopted within our institution for
